Immune-mediated processes in neurodegeneration: where do we stand?

Journal of Neurology

Volumn 263, Issue 9, 2016, Pages 1683-1701

  Fakhoury, Marc ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Immune response; Inflammation; Microglia; Neurodegenerative diseases; T cells

Indexed keywords

PATTERN RECOGNITION RECEPTOR;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MEDIATOR RELEASE; MICROGLIA; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROIMMUNOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; ANIMAL; IMMUNOLOGY; IMMUNOMODULATION; NERVE DEGENERATION; PHYSIOLOGY;

ANIMALS; HUMANS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEUROIMMUNOMODULATION;

EID: 84957974861     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-016-8052-0     Document Type: Review

References (164)

1. Bertram L, Tanzi RE (2005) The genetic epidemiology of neurodegenerative disease. J Clin Invest 115:1449–1457. doi:10.1172/JCI24761
2. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM (2009) Finding the missing heritability of complex diseases. Nature 461:747–753. doi:10.1038/nature08494
3. Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease—a double-edged sword. Neuron 35:419–432
4. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140:918–934. doi:10.1016/j.cell.2010.02.016
5. Newton K, Dixit VM (2012) Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. doi:10.1101/cshperspect.a006049
6. Fakhoury M (2015) Role of immunity and inflammation in the pathophysiology of neurodegenerative diseases. Neurodegener Dis 15:63–69. doi:10.1159/000369933
7. Austin PJ, Moalem-Taylor G (2010) The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol 229:26–50. doi:10.1016/j.jneuroim.2010.08.013
8. Hanamsagar R, Hanke ML, Kielian T (2012) Toll-like receptor (TLR) and inflammasome actions in the central nervous system. Trends Immunol 33:333–342. doi:10.1016/j.it.2012.03.001
9. Lampron A, Elali A, Rivest S (2013) Innate immunity in the CNS: redefining the relationship between the CNS and Its environment. Neuron 78:214–232. doi:10.1016/j.neuron.2013.04.005
10. Zhang E, Lu M (2015) Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol 204:11–20. doi:10.1007/s00430-014-0370-1
11. Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140:805–820. doi:10.1016/j.cell.2010.01.022
12. Facci L, Barbierato M, Marinelli C, Argentini C, Skaper SD, Giusti P (2014) Toll-like receptors 2, -3 and -4 prime microglia but not astrocytes across central nervous system regions for ATP-dependent interleukin-1beta release. Sci Rep 4:6824. doi:10.1038/srep06824
13. Geijtenbeek TB, Gringhuis SI (2009) Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 9:465–479. doi:10.1038/nri2569
14. Chen G, Shaw MH, Kim YG, Nunez G (2009) NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 4:365–398. doi:10.1146/annurev.pathol.4.110807.092239
15. Franchi L, Warner N, Viani K, Nunez G (2009) Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 227:106–128. doi:10.1111/j.1600-065X.2008.00734.x
16. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, Thiyagarajan M, Zarcone T, Fritz G, Friedman AE, Miller BL, Zlokovic BV (2012) A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122:1377–1392. doi:10.1172/JCI58642
17. Beynon V, Cotofana S, Brand S, Lohse P, Mair A, Wagner S, Mussack T, Ochsenkuhn T, Folwaczny M, Folwaczny C, Glas J, Torok HP (2008) NOD2/CARD15 genotype influences MDP-induced cytokine release and basal IL-12p40 levels in primary isolated peripheral blood monocytes. Inflamm Bowel Dis 14:1033–1040. doi:10.1002/ibd.20441
18. Ma Q, An X, Li Z, Zhang H, Huang W, Cai L, Hu P, Lin Q, Tzeng CM (2013) P268S in NOD2 associates with susceptibility to Parkinson’s disease in Chinese population. Behav Brain Funct 9:19. doi:10.1186/1744-9081-9-19
19. Choi AJ, Ryter SW (2014) Inflammasomes: molecular regulation and implications for metabolic and cognitive diseases. Mol Cells 37:441–448. doi:10.14348/molcells.2014.0104
20. Pontillo A, Catamo E, Arosio B, Mari D, Crovella S (2012) NALP1/NLRP1 genetic variants are associated with Alzheimer disease. Alzheimer Dis Assoc Disord 26:277–281. doi:10.1097/WAD.0b013e318231a8ac
21. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT (2013) NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 493:674–678. doi:10.1038/nature11729
22. Mogensen TH (2009) Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 22:240–273. doi:10.1128/CMR.00046-08 (table of contents)
23. Ramos HJ, Gale M Jr (2011) RIG-I like receptors and their signaling crosstalk in the regulation of antiviral immunity. Curr Opin Virol 1:167–176. doi:10.1016/j.coviro.2011.04.004
24. de Rivero Vaccari JP, Brand FJ 3rd, Sedaghat C, Mash DC, Dietrich WD, Keane RW (2014) RIG-1 receptor expression in the pathology of Alzheimer’s disease. J Neuroinflammation 11:67. doi:10.1186/1742-2094-11-67
25. Maragakis NJ, Rothstein JD (2006) Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2:679–689. doi:10.1038/ncpneuro0355
26. Ben Haim L, Carrillo-de Sauvage MA, Ceyzeriat K, Escartin C (2015) Elusive roles for reactive astrocytes in neurodegenerative diseases. Front Cell Neurosci 9:278. doi:10.3389/fncel.2015.00278
27. Perry VH, Nicoll JA, Holmes C (2010) Microglia in neurodegenerative disease. Nat Rev Neurol 6:193–201. doi:10.1038/nrneurol.2010.17
28. Dong Y, Benveniste EN (2001) Immune function of astrocytes. Glia 36:180–190
29. Chastain EM, Duncan DS, Rodgers JM, Miller SD (2011) The role of antigen presenting cells in multiple sclerosis. Biochim Biophys Acta 1812:265–274. doi:10.1016/j.bbadis.2010.07.008
30. Neumann H, Kotter MR, Franklin RJ (2009) Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 132:288–295. doi:10.1093/brain/awn109
31. Kantari C, Pederzoli-Ribeil M, Witko-Sarsat V (2008) The role of neutrophils and monocytes in innate immunity. Contrib Microbiol 15:118–146. doi:10.1159/000136335
32. Christy AL, Walker ME, Hessner MJ, Brown MA (2013) Mast cell activation and neutrophil recruitment promotes early and robust inflammation in the meninges in EAE. J Autoimmun 42:50–61. doi:10.1016/j.jaut.2012.11.003
33. Kumar V, Sharma A (2010) Neutrophils: Cinderella of innate immune system. Int Immunopharmacol 10:1325–1334. doi:10.1016/j.intimp.2010.08.012
34. Savina A, Amigorena S (2007) Phagocytosis and antigen presentation in dendritic cells. Immunol Rev 219:143–156. doi:10.1111/j.1600-065X.2007.00552.x
35. Jain U, Otley AR, Van Limbergen J, Stadnyk AW (2014) The complement system in inflammatory bowel disease. Inflamm Bowel Dis 20:1628–1637. doi:10.1097/MIB.0000000000000056
36. Rus H, Cudrici C, Niculescu F (2005) The role of the complement system in innate immunity. Immunol Res 33:103–112. doi:10.1385/IR:33:2:103
37. Markiewski MM, Lambris JD (2007) The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 171:715–727. doi:10.2353/ajpath.2007.070166
38. Lunemann A, Lunemann JD, Munz C (2009) Regulatory NK-cell functions in inflammation and autoimmunity. Mol Med 15:352–358. doi:10.2119/molmed.2009.00035
39. Urb M, Sheppard DC (2012) The role of mast cells in the defence against pathogens. PLoS Pathog 8:e1002619. doi:10.1371/journal.ppat.1002619
40. Abraham SN, St John AL (2010) Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10:440–452. doi:10.1038/nri2782
41. Fiala M, Chattopadhay M, La Cava A, Tse E, Liu G, Lourenco E, Eskin A, Liu PT, Magpantay L, Tse S, Mahanian M, Weitzman R, Tong J, Nguyen C, Cho T, Koo P, Sayre J, Martinez-Maza O, Rosenthal MJ, Wiedau-Pazos M (2010) IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflammation 7:76. doi:10.1186/1742-2094-7-76
42. Schwartz C, Eberle JU, Voehringer D (2015) Basophils in inflammation. Eur J Pharmacol. doi:10.1016/j.ejphar.2015.04.049
43. Stone KD, Prussin C, Metcalfe DD (2010) IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 125:S73–S80. doi:10.1016/j.jaci.2009.11.017
44. Siracusa MC, Kim BS, Spergel JM, Artis D (2013) Basophils and allergic inflammation. J Allergy Clin Immunol 132:789–801. doi:10.1016/j.jaci.2013.07.046 (quiz 788)
45. Lunnon K, Ibrahim Z, Proitsi P, Lourdusamy A, Newhouse S, Sattlecker M, Furney S, Saleem M, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Coppola G, Geschwind D, Simmons A, Lovestone S, Dobson R, Hodges A, AddNeuroMed C (2012) Mitochondrial dysfunction and immune activation are detectable in early Alzheimer’s disease blood. J Alzheimers Dis 30:685–710. doi:10.3233/JAD-2012-111592
46. Liu GT, Hwang CS, Hsieh CH, Lu CH, Chang SL, Lee JC, Huang CF, Chang HT (2013) Eosinophil-derived neurotoxin is elevated in patients with amyotrophic lateral sclerosis. Mediators Inflamm 2013:421389. doi:10.1155/2013/421389
47. Fulkerson PC, Rothenberg ME (2013) Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 12:117–129. doi:10.1038/nrd3838
48. Wong CK, Ng SS, Lun SW, Cao J, Lam CW (2009) Signalling mechanisms regulating the activation of human eosinophils by mast-cell-derived chymase: implications for mast cell-eosinophil interaction in allergic inflammation. Immunology 126:579–587. doi:10.1111/j.1365-2567.2008.02916.x
49. Luna-Gomes T, Bozza PT, Bandeira-Melo C (2013) Eosinophil recruitment and activation: the role of lipid mediators. Front Pharmacol 4:27. doi:10.3389/fphar.2013.00027
50. Shamri R, Xenakis JJ, Spencer LA (2011) Eosinophils in innate immunity: an evolving story. Cell Tissue Res 343:57–83. doi:10.1007/s00441-010-1049-6
51. Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, Kay AB, Rothenberg ME (2008) Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 38:709–750. doi:10.1111/j.1365-2222.2008.02958.x
52. Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14:463–477. doi:10.1038/nri3705
53. Soulet D, Rivest S (2008) Bone-marrow-derived microglia: myth or reality? Curr Opin Pharmacol 8:508–518. doi:10.1016/j.coph.2008.04.002
54. Gonzalez H, Elgueta D, Montoya A, Pacheco R (2014) Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J Neuroimmunol 274:1–13. doi:10.1016/j.jneuroim.2014.07.012
55. Prinz M, Priller J (2014) Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci 15:300–312. doi:10.1038/nrn3722
56. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57–69. doi:10.1038/nrn2038
57. Gemma C, Bachstetter AD (2013) The role of microglia in adult hippocampal neurogenesis. Front Cell Neurosci 7:229. doi:10.3389/fncel.2013.00229
58. Trudler D, Farfara D, Frenkel D (2010) Toll-like receptors expression and signaling in glia cells in neuro-amyloidogenic diseases: towards future therapeutic application. Mediators Inflamm. doi:10.1155/2010/497987
59. Gao X, Hu X, Qian L, Yang S, Zhang W, Zhang D, Wu X, Fraser A, Wilson B, Flood PM, Block M, Hong JS (2008) Formyl-methionyl-leucyl-phenylalanine-induced dopaminergic neurotoxicity via microglial activation: a mediator between peripheral infection and neurodegeneration? Environ Health Perspect 116:593–598. doi:10.1289/ehp.11031
60. Bodea LG, Wang Y, Linnartz-Gerlach B, Kopatz J, Sinkkonen L, Musgrove R, Kaoma T, Muller A, Vallar L, Di Monte DA, Balling R, Neumann H (2014) Neurodegeneration by activation of the microglial complement-phagosome pathway. J Neurosci 34:8546–8556. doi:10.1523/JNEUROSCI.5002-13.2014
61. Suzumura A (2013) Neuron-microglia interaction in neuroinflammation. Curr Protein Pept Sci 14:16–20
62. Carnevale D, De Simone R, Minghetti L (2007) Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol Disord Drug Targets 6:388–397
63. Zhang S, Wang XJ, Tian LP, Pan J, Lu GQ, Zhang YJ, Ding JQ, Chen SD (2011) CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson’s disease. J Neuroinflammation 8:154. doi:10.1186/1742-2094-8-154
64. Skaper SD, Facci L (2012) Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philos Trans R Soc Lond B Biol Sci 367:3312–3325. doi:10.1098/rstb.2011.0391
65. Skaper SD, Facci L, Giusti P (2014) Mast cells, glia and neuroinflammation: partners in crime? Immunology 141:314–327. doi:10.1111/imm.12170
66. Hucke S, Flossdorf J, Grutzke B, Dunay IR, Frenzel K, Jungverdorben J, Linnartz B, Mack M, Peitz M, Brustle O, Kurts C, Klockgether T, Neumann H, Prinz M, Wiendl H, Knolle P, Klotz L (2012) Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor gamma. Brain 135:1586–1605. doi:10.1093/brain/aws058
67. Gonzalez H, Pacheco R (2014) T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. J Neuroinflammation 11:201. doi:10.1186/s12974-014-0201-8
68. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899. doi:10.1016/j.cell.2010.01.025
69. Paul S, Shilpi, Lal G (2015) Role of gamma-delta (gammadelta) T cells in autoimmunity. J Leukoc Biol 97:259–271. doi:10.1189/jlb.3RU0914-443R
70. Luckheeram RV, Zhou R, Verma AD, Xia B (2012) CD4(+)T cells: differentiation and functions. Clin Dev Immunol 2012:925135. doi:10.1155/2012/925135
71. Dardalhon V, Korn T, Kuchroo VK, Anderson AC (2008) Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 31:252–256. doi:10.1016/j.jaut.2008.04.017
72. Cao C, Arendash GW, Dickson A, Mamcarz MB, Lin X, Ethell DW (2009) Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer’s mice without infiltrating the CNS. Neurobiol Dis 34:63–70. doi:10.1016/j.nbd.2008.12.015
73. Ouyang W, Kolls JK, Zheng Y (2008) The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28:454–467. doi:10.1016/j.immuni.2008.03.004
74. Zambrano-Zaragoza JF, Romo-Martinez EJ, Duran-Avelar Mde J, Garcia-Magallanes N, Vibanco-Perez N (2014) Th17 cells in autoimmune and infectious diseases. Int J Inflam 2014:651503. doi:10.1155/2014/651503
75. Zhang J, Ke KF, Liu Z, Qiu YH, Peng YP (2013) Th17 cell-mediated neuroinflammation is involved in neurodegeneration of abeta1-42-induced Alzheimer’s disease model rats. PLoS ONE 8:e75786. doi:10.1371/journal.pone.0075786
76. Tzartos JS, Craner MJ, Friese MA, Jakobsen KB, Newcombe J, Esiri MM, Fugger L (2011) IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. Am J Pathol 178:794–802. doi:10.1016/j.ajpath.2010.10.043
77. + T-regulatory cells: toward therapy for human diseases. Immunol Rev 223:391–421. doi:10.1111/j.1600-065X.2008.00634.x
78. Pot C, Apetoh L, Kuchroo VK (2011) Type 1 regulatory T cells (Tr1) in autoimmunity. Semin Immunol 23:202–208. doi:10.1016/j.smim.2011.07.005
79. + regulatory T cells, suppress NLRP3 inflammasome activation via an IL-10-dependent mechanism. J Immunol 195:488–497. doi:10.4049/jimmunol.1403225
80. Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S, Lopez-Diaz de Cerio A, Palacios R, Sepulcre J, Moreno B, Gonzalez Z, Fernandez-Diez B, Melero I, Bendandi M, Villoslada P (2008) IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol 38:576–586. doi:10.1002/eji.200737271
81. Choi IS (2012) Immune tolerance by induced regulatory T cells in asthma. Allergy Asthma Immunol Res 4:113–115. doi:10.4168/aair.2012.4.3.113
82. Brun V, Neveu V, Pers YM, Fabre S, Quatannens B, Bastian H, Clerget-Chossat N, Jorgensen C, Foussat A (2011) Isolation of functional autologous collagen-II specific IL-10 producing Tr1 cell clones from rheumatoid arthritis blood. Int Immunopharmacol 11:1074–1078. doi:10.1016/j.intimp.2011.03.001
83. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE (2010) Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol 184:2261–2271. doi:10.4049/jimmunol.0901852
84. + regulatory T cells in an animal model of Parkinson’s disease. J Leukoc Biol 82:1083–1094. doi:10.1189/jlb.0507296
85. Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, Liao B, Appel SH (2011) Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 134:1293–1314. doi:10.1093/brain/awr074
86. + regulatory T cells: more of the same or a division of labor? Immunity 30:626–635. doi:10.1016/j.immuni.2009.05.002
87. Lin X, Chen M, Liu Y, Guo Z, He X, Brand D, Zheng SG (2013) Advances in distinguishing natural from induced Foxp3(+) regulatory T cells. Int J Clin Exp Pathol 6:116–123
88. + regulatory T cells using FACS sorting on scatter plot. J Mol Cell Biol 2:164–169. doi:10.1093/jmcb/mjq007
89. Horwitz DA, Zheng SG, Gray JD (2008) Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol 29:429–435. doi:10.1016/j.it.2008.06.005
90. + T Cells. Front Immunol 5:295. doi:10.3389/fimmu.2014.00295
91. + T-cell memory. Nat Rev Immunol 8:107–119. doi:10.1038/nri2251
92. Saxena A, Martin-Blondel G, Mars LT, Liblau RS (2011) Role of CD8 T cell subsets in the pathogenesis of multiple sclerosis. FEBS Lett 585:3758–3763. doi:10.1016/j.febslet.2011.08.047
93. Zarling S, Berenzon D, Dalai S, Liepinsh D, Steers N, Krzych U (2013) The survival of memory CD8 T cells that is mediated by IL-15 correlates with sustained protection against malaria. J Immunol 190:5128–5141. doi:10.4049/jimmunol.1203396
94. + effector memory T cells. J Immunol 180:7948–7957
95. + T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 78:402–408. doi:10.1212/WNL.0b013e318245d250
96. Junker A, Ivanidze J, Malotka J, Eiglmeier I, Lassmann H, Wekerle H, Meinl E, Hohlfeld R, Dornmair K (2007) Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 130:2789–2799. doi:10.1093/brain/awm214
97. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H (2009) The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132:1175–1189. doi:10.1093/brain/awp070
98. + Treg suppress EAE by TGF-beta- and IFN-gamma-dependent mechanisms. Eur J Immunol 39:3423–3435. doi:10.1002/eji.200939441
99. + regulatory T cells in the recovery from experimental autoimmune encephalomyelitis. J Immunol 180:825–832
100. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T (2009) Regulatory T cells: how do they suppress immune responses? Int Immunol 21:1105–1111. doi:10.1093/intimm/dxp095
101. Larochelle C, Alvarez JI, Prat A (2011) How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett 585:3770–3780. doi:10.1016/j.febslet.2011.04.066
102. Serlin Y, Shelef I, Knyazer B, Friedman A (2015) Anatomy and physiology of the blood-brain barrier. Semin Cell Dev Biol 38:2–6. doi:10.1016/j.semcdb.2015.01.002
103. Fakhoury M, Ryusuke T, Al-Salami H (2015) Drug permeation across the blood-brain barrier: applications of Nanotechnology. Br J Med Med Res. 6:547. doi:10.9734/BJMMR/2015/15493
104. Luissint AC, Artus C, Glacial F, Ganeshamoorthy K, Couraud PO (2012) Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS 9:23. doi:10.1186/2045-8118-9-23
105. Carvey PM, Hendey B, Monahan AJ (2009) The blood-brain barrier in neurodegenerative disease: a rhetorical perspective. J Neurochem 111:291–314. doi:10.1111/j.1471-4159.2009.06319.x
106. Petty MA, Lo EH (2002) Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog Neurobiol 68:311–323
107. Quaegebeur A, Segura I, Carmeliet P (2010) Pericytes: blood-brain barrier safeguards against neurodegeneration? Neuron 68:321–323. doi:10.1016/j.neuron.2010.10.024
108. Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K, Johansson BR, Betsholtz C (2010) Pericytes regulate the blood-brain barrier. Nature 468:557–561. doi:10.1038/nature09522
109. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV (2010) Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68:409–427. doi:10.1016/j.neuron.2010.09.043
110. Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramanathan A, Zlokovic BV (2013) Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun 4:2932. doi:10.1038/ncomms3932
111. Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41–53. doi:10.1038/nrn1824
112. Baeten KM, Akassoglou K (2011) Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke. Dev Neurobiol 71:1018–1039. doi:10.1002/dneu.20954
113. Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16:358–372. doi:10.1038/nrn3880
114. Sastre M, Klockgether T, Heneka MT (2006) Contribution of inflammatory processes to Alzheimer’s disease: molecular mechanisms. Int J Dev Neurosci 24:167–176. doi:10.1016/j.ijdevneu.2005.11.014
115. Forman MS, Lal D, Zhang B, Dabir DV, Swanson E, Lee VM, Trojanowski JQ (2005) Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. J Neurosci 25:3539–3550. doi:10.1523/JNEUROSCI.0081-05.2005
116. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13:432–438. doi:10.1038/nm1555
117. Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U, Miller KR, Prokop S, Kettenmann H, Heppner FL (2013) Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS ONE 8:e60921. doi:10.1371/journal.pone.0060921
118. Marchese M, Cowan D, Head E, Ma D, Karimi K, Ashthorpe V, Kapadia M, Zhao H, Davis P, Sakic B (2014) Autoimmune manifestations in the 3xTg-AD model of Alzheimer’s disease. J Alzheimers Dis 39:191–210. doi:10.3233/JAD-131490
119. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D’Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM (2010) YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol Psychiatry 68:903–912. doi:10.1016/j.biopsych.2010.08.025
120. Yokokura MMN, Yagi S, Yoshikawa E, Kikuchi M, Yoshihara Y, Wakuda T, Sugihara G, Takebayashi K, Suda S, Iwata Y, Ueki T, Tsuchiya KJ, Suzuki K, Nakamura K, Ouchi Y (2011) In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 38:343–351
121. + monocytes in a mouse model of Alzheimer’s disease. Brain 138:2399–2422. doi:10.1093/brain/awv150
122. Baruch K, Rosenzweig N, Kertser A, Deczkowska A, Sharif AM, Spinrad A, Tsitsou-Kampeli A, Sarel A, Cahalon L, Schwartz M (2015) Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer’s disease pathology. Nat Commun 6:7967. doi:10.1038/ncomms8967
123. Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132–144. doi:10.1016/j.freeradbiomed.2013.01.018
124. Bras JM, Singleton A (2009) Genetic susceptibility in Parkinson’s disease. Biochim Biophys Acta 1792:597–603. doi:10.1016/j.bbadis.2008.11.008
125. Chinta SJ, Lieu CA, Demaria M, Laberge RM, Campisi J, Andersen JK (2013) Environmental stress, ageing and glial cell senescence: a novel mechanistic link to Parkinson’s disease? J Intern Med 273:429–436. doi:10.1111/joim.12029
126. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8:382–397. doi:10.1016/S1474-4422(09)70062-6
127. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM (2008) Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28:7687–7698. doi:10.1523/JNEUROSCI.0143-07.2008
128. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ (2008) Synuclein activates microglia in a model of Parkinson’s disease. Neurobiol Aging 29:1690–1701. doi:10.1016/j.neurobiolaging.2007.04.006
129. Rappold PM, Tieu K (2010) Astrocytes and therapeutics for Parkinson’s disease. Neurotherapeutics 7:413–423. doi:10.1016/j.nurt.2010.07.001
130. Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, Schulz-Schaeffer W, Fassbender K (2009) Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging 30:759–768. doi:10.1016/j.neurobiolaging.2007.08.018
131. + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119:182–192. doi:10.1172/JCI36470
132. Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, Zoga M, Tsoutsou A, Boufidou F, Kapaki E, Vassilopoulos D (2007) Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease. Acta Neurol Scand 116:374–379. doi:10.1111/j.1600-0404.2007.00894.x
133. Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, Gasser T, Stoltze L (2007) Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 188:117–127. doi:10.1016/j.jneuroim.2007.05.011
134. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21:404–412. doi:10.1016/j.nbd.2005.08.002
135. Trapp BD, Nave KA (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31:247–269. doi:10.1146/annurev.neuro.30.051606.094313
136. Minagar A (2013) Current and future therapies for multiple sclerosis. Scientifica (Cairo) 2013:249101. doi:10.1155/2013/249101
137. Goris A, Pauwels I, Dubois B (2012) Progress in multiple sclerosis genetics. Curr Genomics 13:646–663. doi:10.2174/138920212803759695
138. O’Gorman C, Lucas R, Taylor B (2012) Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms. Int J Mol Sci 13:11718–11752. doi:10.3390/ijms130911718
139. Denic A, Wootla B, Rodriguez M (2013) CD8(+) T cells in multiple sclerosis. Expert Opin Ther Targets 17:1053–1066. doi:10.1517/14728222.2013.815726
140. El Waly B, Macchi M, Cayre M, Durbec P (2014) Oligodendrogenesis in the normal and pathological central nervous system. Front Neurosci 8:145. doi:10.3389/fnins.2014.00145
141. Airas L, Dickens AM, Elo P, Marjamaki P, Johansson J, Eskola O, Jones PA, Trigg W, Solin O, Haaparanta-Solin M, Anthony DC, Rinne J (2015) In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis. J Nucl Med 56:305–310. doi:10.2967/jnumed.114.149955
142. Liu Y, Bando Y, Vargas-Lowy D, Elyaman W, Khoury SJ, Huang T, Reif K, Chitnis T (2010) CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J Neurosci 30:2025–2038. doi:10.1523/JNEUROSCI.4272-09.2010
143. Fernando V, Omura S, Sato F, Kawai E, Martinez NE, Elliott SF, Yoh K, Takahashi S, Tsunoda I (2014) Regulation of an autoimmune model for multiple sclerosis in Th2-biased GATA3 transgenic mice. Int J Mol Sci 15:1700–1718. doi:10.3390/ijms15021700
144. Martinez NE, Karlsson F, Sato F, Kawai E, Omura S, Minagar A, Grisham MB, Tsunoda I (2014) Protective and detrimental roles for regulatory T cells in a viral model for multiple sclerosis. Brain Pathol 24:436–451. doi:10.1111/bpa.12119
145. Kallaur AP, Oliveira SR, Colado Simao AN, Delicato de Almeida ER, Kaminami Morimoto H, Lopes J, de Carvalho Jennings Pereira WL, Marques Andrade R, Muliterno Pelegrino L, Donizete Borelli S, Kaimen-Maciel DR, Reiche EM (2013) Cytokine profile in relapsingremitting multiple sclerosis patients and the association between progression and activity of the disease. Mol Med Rep 7:1010–1020. doi:10.3892/mmr.2013.1256
146. Graber JJ, Ford D, Zhan M, Francis G, Panitch H, Dhib-Jalbut S (2007) Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J Neuroimmunol 185:168–174. doi:10.1016/j.jneuroim.2007.01.011
147. Kooi EJ, Strijbis EM, van der Valk P, Geurts JJ (2012) Heterogeneity of cortical lesions in multiple sclerosis: clinical and pathologic implications. Neurology 79:1369–1376. doi:10.1212/WNL.0b013e31826c1b1c
148. Rinaldi L, Gallo P, Calabrese M, Ranzato F, Luise D, Colavito D, Motta M, Guglielmo A, Del Giudice E, Romualdi C, Ragazzi E, D’Arrigo A, Dalle Carbonare M, Leontino B, Leon A (2006) Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. Brain 129:1993–2007. doi:10.1093/brain/awl179
149. von Budingen HC, Kuo TC, Sirota M, van Belle CJ, Apeltsin L, Glanville J, Cree BA, Gourraud PA, Schwartzburg A, Huerta G, Telman D, Sundar PD, Casey T, Cox DR, Hauser SL (2012) B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest 122:4533–4543. doi:10.1172/JCI63842
150. Lehmann-Horn K, Kronsbein HC, Weber MS (2013) Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Ther Adv Neurol Disord 6:161–173. doi:10.1177/1756285612474333
151. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH, HERMES Trial Group (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688. doi:10.1056/NEJMoa0706383
152. Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH, OLYMPUS trail group (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66:460–471. doi:10.1002/ana.21867
153. Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41:118–130. doi:10.1159/000351153
154. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC (2011) Amyotrophic lateral sclerosis. Lancet 377:942–955. doi:10.1016/S0140-6736(10)61156-7
155. Hovden H, Frederiksen JL, Pedersen SW (2013) Immune system alterations in amyotrophic lateral sclerosis. Acta Neurol Scand 128:287–296. doi:10.1111/ane.12125
156. Vucic S, Rothstein JD, Kiernan MC (2014) Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci 37:433–442. doi:10.1016/j.tins.2014.05.006
157. Lewis KE, Rasmussen AL, Bennett W, King A, West AK, Chung RS, Chuah MI (2014) Microglia and motor neurons during disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis: changes in arginase1 and inducible nitric oxide synthase. J Neuroinflammation 11:55. doi:10.1186/1742-2094-11-55
158. Lasiene J, Yamanaka K (2011) Glial cells in amyotrophic lateral sclerosis. Neurol Res Int 2011:718987. doi:10.1155/2011/718987
159. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW (2006) Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312:1389–1392. doi:10.1126/science.1123511
160. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, Takahashi R, Misawa H, Cleveland DW (2008) Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 11:251–253. doi:10.1038/nn2047
161. Woodruff TM, Costantini KJ, Crane JW, Atkin JD, Monk PN, Taylor SM, Noakes PG (2008) The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol 181:8727–8734
162. Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, Song S, Likhite S, Murtha MJ, Foust KD, Rao M, Eagle A, Kammesheidt A, Christensen A, Mendell JR, Burghes AH, Kaspar BK (2011) Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 29:824–828. doi:10.1038/nbt.1957
163. Sta M, Sylva-Steenland RM, Casula M, de Jong JM, Troost D, Aronica E, Baas F (2011) Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol Dis 42:211–220. doi:10.1016/j.nbd.2011.01.002
164. Mantovani S, Garbelli S, Pasini A, Alimonti D, Perotti C, Melazzini M, Bendotti C, Mora G (2009) Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J Neuroimmunol 210:73–79. doi:10.1016/j.jneuroim.2009.02.012